EARLY STAGE TRIPLE-NEGATIVE BREAST CARCINOMA
Clinical trials for EARLY STAGE TRIPLE-NEGATIVE BREAST CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new EARLY STAGE TRIPLE-NEGATIVE BREAST CARCINOMA trials appear
Sign up with your email to follow new studies for EARLY STAGE TRIPLE-NEGATIVE BREAST CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Custom-Made vaccine takes on tough breast cancer
⭐️ VACCINE ⭐️ Recruiting nowThis early-stage study tests a personalized vaccine made from a patient's own tumor, combined with immunotherapy drugs, for triple negative breast cancer. The goal is to see if the vaccine is safe and can help the immune system attack cancer cells. About 18 adults with various st…
Matched conditions: EARLY STAGE TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: Emory University • Aim: ⭐️ VACCINE ⭐️
Last updated May 26, 2026 04:17 UTC
-
New drug combo aims to wipe out early breast cancer before surgery
Disease control Recruiting nowThis study tests whether adding the drug ivonescimab to standard chemotherapy before surgery can improve outcomes for people with early-stage triple-negative breast cancer. About 34 participants will receive the combination every three weeks for six cycles, then undergo surgery t…
Matched conditions: EARLY STAGE TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: Cedars-Sinai Medical Center • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
Could a shorter, safer chemo regimen beat standard care for aggressive breast cancer?
Disease control Recruiting nowThis study compares a shorter chemotherapy-immunotherapy combination without anthracyclines to the usual treatment for early-stage triple-negative breast cancer. About 2,400 participants will receive either the experimental shorter regimen or standard care. The goal is to see if …
Matched conditions: EARLY STAGE TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
BREAST CANCER BREAKTHROUGH: could less treatment be just as effective?
Disease control Recruiting nowThis study is for people with early-stage triple-negative breast cancer who had a complete response (no cancer left) after chemotherapy plus the immunotherapy drug pembrolizumab. The trial compares receiving more pembrolizumab versus simply being watched (observation) to see if t…
Matched conditions: EARLY STAGE TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated May 04, 2026 16:22 UTC
-
New platform aims to predict which cancer treatments will work
Knowledge-focused Recruiting nowThis study collects tissue samples from people with various advanced or early-stage cancers to train a diagnostic platform called Elephas. The goal is to see how accurately it can predict whether a patient will respond to immunotherapy or chemoimmunotherapy. About 324 participant…
Matched conditions: EARLY STAGE TRIPLE-NEGATIVE BREAST CARCINOMA
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated May 26, 2026 04:12 UTC